Biotech Dip Could Be a Buying Opportunity

Biotech ETFs XBI and XLV are pacing for their worst week in a long time, but don't count them out just yet

Oct 27, 2017 at 2:43 PM
facebook twitter linkedin


It's been a rough week for biotech stocks, due to a handful of earnings disappointments and concerns about Amazon's (AMZN) entry into the pharmaceutical sector. As such, the SPDR S&P Biotech ETF (XBI) is pacing for its worst week since late June, while the Health Care Select Sector SPDR Fund (XLV) is set for its worst week in a year. However, if recent history is any indicator, today's biotech weakness could be a buying opportunity. Below, we outline why we're watching XBI and XLV in November, and name one drug stock that could be due for a big bounce.

Biotech stocks have been the best to own in November, with the XBI averaging a gain of 3.84% during the month, going back 10 years -- the best of all exchange-traded funds (ETFs) we track. Further, the fund was positive 70% of the time, according to Schaeffer's Senior Quantitative Analyst Rocky White. XLV, meanwhile, has also ended November higher 70% of the time, racking up an average gain of 1.28%.

After eight straight days of losses, XBI shares were last seen 1.2% higher at $82.76. Another 3.84% surge over the next month would put the ETF just shy of $86 -- and within striking distance of its two-year high, touched Oct. 6. What's more, similar pullbacks have represented buying opportunities on XBI since early 2016, when the ETF began a series of higher highs and lows. More recently, the fund's pullbacks have been contained by its ascending 80-day moving average.

XBI chart

XLV touched a record high of $84.30 just Monday, but has since pulled back to trade at $82.09, down 0.1% on the day. The fund has been making a series of higher highs and lows since the presidential election, ushered higher atop its 80-day trendline, and another 1.28% jump in November would put XLV shares around $83.14.

XLV chart

Should the ETFs rebound in November, a short squeeze could add fuel to the fire. Short interest on XBI represents nearly two weeks' worth of pent-up buying demand, at the fund's average pace of trading. Meanwhile, XLV has roughly a week's worth of short interest on the books.

For speculators looking for an individual biotech stock with potential, Sarepta Therapeutics Inc (NASDAQ:SRPT) could be flashing "buy," if history repeats. SRPT stock notched an annual high of $52.67 last week, but retreated this week, despite the company reporting a smaller-than-expected third-quarter loss and lifting its full-year sales forecast. The security is now within one standard deviation of its 40-day moving average, after a lengthy spell above this trendline, which has been bullish in the past.

After the last eight pullbacks to the 40-day, SRPT shares went on to enjoy an average one-week return of 2.05%, and was higher 75% of the time. One month after pullbacks, the equity was higher 71% of the time, with an average return of 15.72%! A similar rally over the next month would put SRPT stock -- last seen trading around $48.14 -- at $55.70, in territory not charted in over a year.

SRPT stock chart

 

Sarepta stock could also enjoy a short squeeze. Short interest accounts for nearly 20% of the security's total available float, and would take more than five sessions to repurchase, at SRPT's average pace of trading.

 

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Master Portfolio Trial
 


 


 
Special Offers from Schaeffer's Trading Partners